Navigation Links
Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Date:12/7/2010

rmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage pre clinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate," "believe," "estimate," "expect," "expectation," "should," "would," "project," "plan," "predict," "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past res
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... Conn. , Aug. 21, 2014  Aptuit ... West Lafayette, Indiana , has enhanced ... and characterization of small and large molecules, including ... of the Bruker maXisPlus Q-TOF mass spectrometer. ... Goldman , CEO, Aptuit, said, "The expanded large ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
... 6 TargeGen, Inc. today announced that,the Company,s ... and the,Company plans to initiate a multi-center clinical ... highly selective JAK2 inhibitor in,January, 2008. Additionally, TargeGen ... will be made at the 2007 ASH Conference,(Atlanta, ...
... Inc. (Nasdaq: BCRX ) today provided an ... Forodesine HCl Data to be Presented at American ... Chair, Dermatology, The University of,Texas M.D. Anderson Cancer ... Phase I/II clinical study of oral forodesine HCl ...
Cached Medicine Technology:TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH 2BioCryst Provides Forodesine HCl Update 2BioCryst Provides Forodesine HCl Update 3BioCryst Provides Forodesine HCl Update 4BioCryst Provides Forodesine HCl Update 5
(Date:8/22/2014)... According to the new research report "Isocyanate ... & Forecast to 2019" defines and segments the ... the market value. The isocyanate material market value ... a significant CAGR from 2014 to 2019. , ... spread through 286 pages and in-depth TOC on ...
(Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
(Date:8/22/2014)... 2014 The report "Higher Education ... & Compliance, Campus Technology, Student & Curriculum, Performance ... defines and segments the global Higher Ed market ... forecasting of market sizes. The report also identifies ... opportunities impacting it along with the adoption trends. ...
(Date:8/22/2014)... 2014 A new study finds a wide range ... be related to key environmental exposuresin children with Crohn,s disease ... journal of the Crohn,s & Colitis Foundation of America ... Williams & Wilkins , a part of Wolters Kluwer ... of alterations of DNA in several regions of the genome ...
(Date:8/22/2014)... of Alzheimer,s disease can be slowed and some ... that is found in pomegranate. Also, the ... arthritis and Parkinson,s disease could be reduced, according ... by University of Huddersfield scientist Dr Olumayokun Olajide, ... products. , Now, a new phase of research ...
Breaking Medicine News(10 mins):Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2
... In a new reflection on the dangers currently gripping humanity, ... to invest in public health and not arms. ... any noble heart, said Castro in his recent article broadcast ... feature, Castro condemned the construction of a "wonderful submarine" in ...
... far better than drinking water, researchers said. ,There ... cups of tea can reduce the risk of heart attacks. ... King's College London, it is a wrong belief that tea ... as it contains antioxidants. It does not dehydrate you, Mirror ...
... a new outbreak of avian flu at three poultry farms ... ,Laboratory tests confirmed the presence of H5N1, a ... three farms in Chak Shehzad, where about 12,000 birds died ... and Livestock Ministry. ,There were no reports of ...
... combination asthma therapy, SYMBICORT leads to significant improvements ... patient-reported satisfaction with asthma treatment, versus its ... ,SYMBICORT is a recently approved, combination therapy indicated ... patients 12 years of age and older. SYMBICORT ...
... comprehensive survey carried out by the World Conservation Union (IUCN) ... threatened with extinction. ,Unless the trend is ... able to meet its self-imposed target of halting biodiversity loss ... that live in Europe and western Russia, some 15 percent ...
... at Arizona State University has used molecular biology tricks to ... with the ones that occurred naturally. ... new proteins in a fraction of the three billion years ... led to some surprisingly new lessons on how to optimize ...
Cached Medicine News:Health News:Combo Therapy may Be Highly Beneficial in Asthma Control 2Health News:One-sixth of Europe's Mammals Face Extinction, Warns Conservation Experts 2
... and fourth year medical students on ... easy access in a rapid-fire Q&A ... lab coat pocket, this reference is ... prior to surgical rounds as well ...
With its extensive content and custom-designed user interface, Schwartz Principles of Surgery, PDA Edition enables you quick access to the answers you need to make the right diagnosis or initiate a t...
This handy reference contains all of the essential information that surgical residents and medical students need to have at their fingertips for day-to-day patient care....
This book includes orthopedic, reproductive, renal, cardiovascular, GI, and respiratory problems; and other common conditions....
Medicine Products: